Skip to Content

Bevyxxa FDA Approval History

FDA Approved: Yes (First approved June 23, 2017)
Brand name: Bevyxxa
Generic name: betrixaban
Dosage form: Capsules
Company: Portola Pharmaceuticals, Inc.
Treatment for: Prevention of Venous Thromboembolism

Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized for an acute medical illness.

Development Timeline for Bevyxxa

DateArticle
Jun 23, 2017Approval FDA Approves Bevyxxa (betrixaban) for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
Dec 23, 2016Portola Pharmaceuticals Announces FDA Accepts NDA for Priority Review for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
Oct 25, 2016Portola Pharmaceuticals Submits NDA to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.